Ligand Pharmaceuticals Incorporated (LGND): Price and Financial Metrics
Ligand Pharmaceuticals Incorporated (LGND)
Today's Latest Price: $85.92 USD
Updated Nov 27 1:00pm
Add LGND to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
LGND Stock Summary
- Price to trailing twelve month operating cash flow for LGND is currently 29.6, higher than 85.74% of US stocks with positive operating cash flow.
- With a year-over-year growth in debt of -28.46%, Ligand Pharmaceuticals Inc's debt growth rate surpasses only 11.04% of about US stocks.
- Ligand Pharmaceuticals Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 25.74%, greater than the shareholder yield of 91.09% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Ligand Pharmaceuticals Inc, a group of peers worth examining would be KMPH, AKTS, AXDX, QTWO, and GNMK.
- Visit LGND's SEC page to see the company's official filings. To visit the company's web site, go to www.ligand.com.
LGND Stock Price Chart Interactive Chart >
LGND Price/Volume Stats
| Current price | $85.92 | 52-week high | $127.80 |
| Prev. close | $87.41 | 52-week low | $57.24 |
| Day low | $85.03 | Volume | 175,300 |
| Day high | $89.29 | Avg. volume | 380,983 |
| 50-day MA | $90.11 | Dividend yield | N/A |
| 200-day MA | $99.54 | Market Cap | 1.38B |
Ligand Pharmaceuticals Incorporated (LGND) Company Bio
Ligand Pharmaceuticals develops therapies that address the unmet medical needs of patients for a range of diseases, including hepatitis, multiple myeloma, muscle wasting, Alzheimers disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis, and osteoporosis. The company was founded in 1987 and is based in La Jolla, California.
LGND Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $85.92 | $28.44 | -66% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Ligand Pharmaceuticals Inc. To summarize, we found that Ligand Pharmaceuticals Inc ranked in the 24th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for LGND, they are:
- Interest coverage, a measure of earnings relative to interest payments, is 0.26 -- which is good for besting just 24.31% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
- Ligand Pharmaceuticals Inc's weighted average cost of capital (WACC) is 11%; for context, that number is higher than 77.82% of tickers in our DCF set.
- Ligand Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than just 0% of US stocks with positive free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -66% |
| 1% | -66% |
| 2% | -66% |
| 3% | -65% |
| 4% | -65% |
| 5% | -65% |
ABC, SNN, RMD, VIVO, and A can be thought of as valuation peers to LGND, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...